Introduction {#sec1_1}
============

While diabetic neuropathy (DN) has several clinical, electrophysiologic distribution patterns (polyneuropathy, PN \[symmetric, distal\], multiple mononeuropathy \[asymmetric, distal/proximal\], mononeuropathy \[focal\], etc.), it remains uncertain which pattern is the most common \[[@B1], [@B2], [@B3], [@B4]\]. To examine this question, we present data of clinical, electrophysiologic DN patterns with atherosclerosis tests.

Methods {#sec1_2}
=======

We enrolled 323 type 2 diabetes subjects. All were referred for neuropathy screening irrespective of symptoms. The diagnostic criteria of type 2 diabetes and DN conformed to the published criteria \[[@B1], [@B2]\]. Subjects were 206 men and 117 women: most were elderly (mean age 64.1 years \[51--79 years\]); mean disease duration of 12.0 years (5--19 years); mean HbA1C 8.7% (5.1--12.1%). Half of the subjects (*n* = 142) were untreated; the rest (*n* = 181) were receiving oral sulphonylurea, thiazolidine derivatives, dipeptidyl peptidase-4 inhibitors, and/or insulin, and had HbA1C values ranging from 5.1 to 8.9%. Other than diabetes, none had comorbid diseases that might contribute to neuropathy (e.g., alcohol, vitamin deficiency, drugs \[chemotherapy, etc.\], toxins \[lead, etc.\], uremia, collagen/granulomatous diseases, neoplasm, or history of familial neuropathies) \[[@B1], [@B2], [@B3]\]. All patients were able to walk independently. A total of 28% of patients had numbness, pain, etc., in the extremities.

In order to explore the diversity of neuropathy, we defined DN by nerve conduction study (NCS), irrespective of subjective symptoms. We performed a standard nerve conduction study NCS \[[@B2]\] in all patients with an electromyography computer (Neuropack M2; Nihon Kohden Inc., Tokyo, Japan) on both sides of the median, ulnar, tibial, peroneal, and sural nerves to identify any abnormalities of distal latencies, conduction velocity, F-wave latency, or evidence of conduction block (all indicating demyelination); or abnormalities of compound muscle action potential or sensory nerve action potential (indicating axonal damage) \[[@B2]\]. The patterns of neuropathies were classified as mononeuropathy (focal, uni- or bilateral − a typical example is uni- or bilateral carpal tunnel syndrome − excluding cranial in the present study), multiple mononeuropathy (often asymmetric, sometimes proximal), and PN (symmetric, distal) \[[@B2], [@B3], [@B4]\]. For PN, we used Dyck\'s criteria 7, i.e., a total of 5 nerve conduction deviates \[[@B2]\]. Demyelination and axonal damage were determined by the threshold of NCS as described previously \[[@B5]\]. We also performed atherosclerosis tests: (1) cardio-ankle vascular stiffness index (CAVI) \[[@B6]\]; and (2) duplex carotid ultrasonography. CAVI is an atherosclerosis measure using a pulse wave velocity but independent from blood pressure (VaSera; Fukuda Denshi Inc., Tokyo, Japan) \[[@B6]\]. We obtained intima-media thickness (IMT) and the plaque score (PS) of the carotid arteries by EUB-525 (Hitachi, Inc., Tokyo, Japan). Data were analyzed by Student\'s *t* test and Mann-Whitney U-test.

Results {#sec1_3}
=======

Among 323 referred subjects, 235 patients (73%) had DN. Subjective symptoms (numbness, pain, etc.) were noted in 18--52% (39% overall) among those with NCS-determined DN; no subjective symptoms were noted in those without DN (28% of subjects had subjective symptoms). The rest (88 subjects) were treated as the controls. Regarding the pattern of neuropathy, the most common was multiple mononeuropathy (26%), followed by bilateral mononeuropathy (18%), PN (16%), and unilateral mononeuropathy (12%); altogether mononeuropathies \[unilateral, bilateral, and multiple\] comprised 56% of cases (Table [1a](#T1){ref-type="table"}). Regarding the type of neuropathy, mononeuropathy cases tended to have demyelination, while PN cases tended to have a combination of demyelination and axonal damage, although none of these differences reached statistical significance. Regarding the duration of diabetes, duration in control subjects (8.6 years) was shorter than that in MNB (12.5 years), MMN (14.8 years), and PN (17.4 years) (*p* \< 0.05, 0.01) (Table [1b](#T1){ref-type="table"}). Concerning the severity of diabetes, compared with HbA1C in control subjects, that in PN alone was significantly increased (*p* \< 0.05). In terms of atherosclerotic markers, compared to CAVI, IMT and PS in control subjects, those in MNB, MMN, and PN were significantly increased (*p* \< 0.05, 0.01) (Table [1b](#T1){ref-type="table"}).

Discussion {#sec1_4}
==========

The question of which clinical, electrophysiologic pattern is the most common in DN remains to be clarified. Our results showed that the most common was multiple mononeuropathy (26%), followed by bilateral mononeuropathy (18%), PN (16%), and unilateral mononeuropathy (12%). Of these, PN mainly represents metabolic disorders due to hyperglycemia such as polyol shunting, accumulation of advanced glycation end products, etc. \[[@B2], [@B3]\]. In contrast, mono/multiple-neuropathy mainly represents mechanical compression or entrapment due to focal ischemia, inflammation, etc. \[[@B2], [@B7], [@B8], [@B9], [@B10]\]. Our study results also showed that the duration of diabetes was shortest in the control group (8.6 years), longer in unilateral mononeuropathy (9.1 years), bilateral mononeuropathy (12.5 years), and multiple mononeuropathy (14.8 years), and longest in PN (17.4 years) (*p* \< 0.01). Risks of atherosclerosis were not associated with mononeuropathy, but were closely associated with multiple mononeuropathy and PN (*p* \< 0.01). However, this association might simply reflect the duration of diabetes, since the relation was noted only in groups with duration \>10 years. These observations suggest that DN might start as mononeuropathy, and then develop into multiple mononeuropathy and ultimately PN.

This study has several limitations. We analyzed NCS data. However, NCS represents thick myelinated nerve fiber function alone. Small fiber sensory neuropathy and autonomic neuropathy can still occur in isolation. Also, we performed this study with a small number of patients, no prospective study, no stratification by subjective symptom, and no metabolically normal control. In order to confirm the DN progression suggested by our findings, prospective, single large cohort studies will be necessary.

In conclusion, our study results indicate that (multiple) mononeuropathy is the most common distribution pattern in DN.
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###### 

Nerve conduction study findings in diabetic patients

###### 

**a** Patterns and types of diabetic neuropathy

                                                           Demyelination (%)   Axonal damage (%)   Demyelination + axonal damage (%)   Patients (%)   Patients, *n*   Subjective symptom (%)   
  ------------------------------------------------- ------ ------------------- ------------------- ----------------------------------- -------------- --------------- ------------------------ ----
  Normal/none                                       0      0                   0                   27                                                                 88                       0
  Mononeuropathy (unilateral)                       60.5   18.4                21.1                12                                  30             56              38                       18
  Mononeuropathy (one nerve, bilateral affection)   50.8   5.1                 42.4                18                                  30             56              59                       27
  Multiple mononeuropathy                           38.8   11.8                49.4                26                                                 56              85                       48
  Distal polyneuropathy                             9.4    5.7                 84.9                16                                                                 53                       52

###### 

**b** Relationship between diabetic neuropathy and disease duration, severity (HbA1C), and atherosclerotic markers

            Neuropathy                                        Diabetes   Atherosclerotic markers                                                                                                                                                  
  --------- ------------------------------------------------- ---------- ---------------------------------------- --------------------------------------- ---------------------------------------- -- -- ---------------------------------------- ----------------------------------------
  Pattern   normal/none                                       74         8.6                                      8.7                                     38.7                                           35.1                                     7
            mononeuropathy (unilateral)                       30         9.1                                      8.6                                     20.8                                           40                                       12
            mononeuropathy (one nerve, bilateral affection)   47         12.5[\*](#T1F1){ref-type="table-fn"}     8.3                                     48.5                                           67.7[\*\*](#T1F2){ref-type="table-fn"}   14.7[\*\*](#T1F2){ref-type="table-fn"}
            multiple mononeuropathy                           69         14.8\*                                   8.7                                     54.9                                           47                                       27.5[\*\*](#T1F2){ref-type="table-fn"}
            distal polyneuropathy                             46         17.4[\*\*](#T1F2){ref-type="table-fn"}   9.7[\*\*](#T1F2){ref-type="table-fn"}   66.7[\*\*](#T1F2){ref-type="table-fn"}         60\*                                     27.5[\*\*](#T1F2){ref-type="table-fn"}
                                                                                                                                                                                                                                                  
  Type      demyelinating                                     73         13[\*](#T1F1){ref-type="table-fn"}       8.9                                     42.6                                           47.6                                     22.2[\*\*](#T1F2){ref-type="table-fn"}
            axonal damage                                     16         13.4[\*](#T1F1){ref-type="table-fn"}     7.5                                     54.5                                           30                                       20
            Demyelinating +axonal damage                      103        14.7[\*\*](#T1F2){ref-type="table-fn"}   8.9                                     56.9[\*](#T1F1){ref-type="table-fn"}           62.4[\*\*](#T1F2){ref-type="table-fn"}   22.1[\*\*](#T1F2){ref-type="table-fn"}

\*,\*\*: Statistical significance between normal and each respective square.

*p* \< 0.05

*p* \< 0.01 .CAVI, cardio-ankle vascular stiffness index; IMT, intima-media thickness; PS, plaque score.
